AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Chinese Obesity Drug HRS9531: A Potential Rival to Eli Lilly's Zepbound with Promising Results in Late-Stage Trial
ByAinvest
Wednesday, Jul 16, 2025 1:23 pm ET1min read
Chinese drugmaker Hengrui Pharma and its US partner Kailera Therapeutics have reported positive data for their experimental obesity drug, HRS9531. The weekly injection helped patients lose an average of 18% of their body weight, exceeding the placebo weight loss. The companies plan to file for approval in China and conduct global studies, positioning the drug as a potential competitor to Eli Lilly's Zepbound.
Chinese drugmaker Hengrui Pharma and its US partner Kailera Therapeutics have announced positive results from a Phase 3 trial for their experimental obesity drug, HRS9531. The weekly injection demonstrated significant weight loss, with patients losing an average of 18% of their body weight over 48 weeks. This performance exceeded the placebo group by 16% [1].The trial, conducted in China, enrolled 567 adults with obesity or overweight and at least one weight-related medical condition. Participants were randomized to receive either a 2 milligram, 4 milligram, or 6 milligram weekly injection of HRS9531, or placebo, for 48 weeks. The drug showed a favorable safety profile, with most adverse events being mild to moderate and gastrointestinal-related [2].
Hengrui plans to submit a New Drug Application (NDA) in China, while Kailera is advancing HRS9531 to global clinical trials under the name KAI-9531. The companies aim to evaluate higher doses and longer treatment durations to expand the drug's potential [2].
The success of HRS9531 positions it as a potential competitor to Eli Lilly's Zepbound, which has shown similar efficacy in clinical trials. The results of HRS9531 suggest it has "best-in-class potential" and could offer a new treatment option for patients struggling with obesity [1].
References:
[1] https://www.biopharmadive.com/news/kailera-hengrui-obesity-drug-results-china/753050/
[2] https://www.biospace.com/press-releases/hengrui-pharma-and-kailera-therapeutics-report-positive-topline-data-from-phase-3-obesity-trial-in-china-of-dual-glp-1-gip-receptor-agonist-hrs9531
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet